{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021115","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.662211+00:00","generated_at":"2026-06-02T19:07:43.777093+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AbCellera Q1 2024 revenue $10.0M, net loss $40.6M; pipeline metrics grow","bullets":["Revenue of $10.0M ($9.8M research fees, $0.2M licensing) down 18% from $12.2M in Q1 2023.","Net loss of $40.6M ($0.14 per share) compared to net loss of $40.1M in Q1 2023.","R&D expenses fell to $39.3M from $52.6M; cash & securities $725.3M plus $240M non-dilutive funding.","Cumulative partner-initiated program starts 90 (up 20% YoY) and molecules in clinic 13 (up 44% YoY).","Announced collaborations with Biogen for neurological antibodies and with Viking/ArrowMark to launch biotechs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021115","json":"https://secwatch.observer/filing/0001628280-24-021115.json","markdown":"https://secwatch.observer/filing/0001628280-24-021115.md","text":"https://secwatch.observer/filing/0001628280-24-021115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/0001628280-24-021115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/abcl-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:07:43.777093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2af9583ab72c078ee81e08704e06efa4557fa51f","claim":"AbCellera Biologics Inc. reported quarter ended March 31, 2024 results: revenue $10.0 million, net income Net loss of $40.6 million, EPS $(0.14) per share.","evidence_excerpt":"● Revenue – Total revenue was $10.0 million, compared to $12.2 million in Q1 2023. Partnerships generated research fees of $9.8 million, compared to $10.6 million in Q1 2023. Licensing revenue was $0.2 million. ● Research & Development (R&D) Expenses – R&D expenses were $39.3 million, compared to $52.6 million in Q1 2023, reflecting underlying continued growth in program execution, platform development, and investments in internal programs, partially offset by the non-recurrence of specific one-time investments in co-development and internal programs. ● Sales & Marketing (S&M) Expenses – S&M expenses were $3.4 million, compared to $3.8 million in Q1 2023. ● General & Administrative (G&A) Expenses – G&A expenses were $17.4 million, compared to $15.1 million in Q1 2023. ● Net Loss – Net loss of $40.6 million, or $(0.14) per share on a basic and diluted basis, compared to net loss of $40.1 million, or $(0.14) per share on a basic and diluted basis in Q1 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/0001628280-24-021115-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.0 million"},{"label":"Net income","value":"Net loss of $40.6 million"},{"label":"EPS","value":"$(0.14) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}